Foundation Stone Marks a Milestone for High-Value Pharmaceutical Manufacturing at Orascom Industrial Parks
Egypt has taken a significant step toward strengthening its biopharmaceutical manufacturing capabilities with the laying of the foundation stone for the GENNVAX vaccine manufacturing facility, set to become the largest fully integrated vaccine production complex in the region. Located within Sokhna Industrial Development Complex (SIDC), Orascom Industrial Parks’ (Orascom IP) first development, located in the Suez Canal Economic Zone (SCZone), the project represents a strategic move toward localizing biological medicines and reinforcing long-term healthcare security.
Held in December 2025, the foundation stone ceremony brought together senior government officials, ambassadors, and leaders from Egypt’s healthcare and pharmaceutical sectors. The high-level attendance reflected the project’s national importance and its alignment with Egypt Vision 2030, particularly the state’s focus on localizing critical industries with strong economic and social impact.
Designed as a fully integrated manufacturing complex, the GENNVAX facility will operate across the full vaccine production value chain, covering both upstream and downstream processes. Backed by a total investment of USD 150 million, the project is expected to play a central role in advancing vaccine localization, enhancing export readiness, and strengthening Egypt’s position as a regional pharmaceutical manufacturing hub serving Africa and the Middle East.
Once operational, the facility will produce 29 vaccines and serums through technology transfer agreements with 15 international partners. In addition, annual production capacity is expected to reach up to 270 million doses per production line operating on a two-shift system. In parallel, the project is expected to generate between 500 and 700 direct jobs, contributing to employment and skills development within one of Egypt’s most advanced industrial sectors.
The project’s location within Orascom Industrial Parks’ integrated ecosystem at the SCZone is a key enabler of its long-term success. This area offers advanced infrastructure, reliable utilities, and direct access to logistics corridors and export routes, creating an environment suited to high-value pharmaceutical manufacturing that meets strict global quality standards.
GENNVAX has also been awarded the Golden License issued by the Prime Minister, recognizing its expected contribution to foreign currency generation through exports. The facility has been designed in line with the highest international benchmarks, including World Health Organization Prequalification (WHO PQ) and European Good Manufacturing Practice (GMP) standards, ensuring access to international procurement channels.
Beyond that, sustainability and knowledge transfer are core elements of the project. The facility incorporates energy-efficient systems and solar solutions, while the GENNVAX Academy for Continuing Medical Education supports capacity building for regulatory and healthcare professionals.
For Orascom Industrial Parks, the GENNVAX project reflects a continued focus on enabling complex, future-oriented industries that align with national priorities and deliver long-term economic and strategic value.
